<DOC>
	<DOCNO>NCT00538239</DOCNO>
	<brief_summary>The purpose study determine whether maintenance therapy oral AP23573 ( ridaforolimus ) , prevent control tumor growth prolong period time patient metastatic soft-tissue bone sarcoma respond chemotherapy , result clinically significant improvement progression-free survival compare oral placebo .</brief_summary>
	<brief_title>Ridaforolimus Treatment Sarcoma-SUCCEED ( Sarcoma Multi-Center Clinical Evaluation Efficacy Ridaforolimus ) ( 8669-011 AM6 )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Confirmed diagnosis metastatic softtissue bone sarcoma Ongoing complete response , partial response , stable disease ( RECIST ) minimum 4 cycle ( maximum 12 month ) one first , second , third line prior cytotoxic chemotherapy metastatic disease Eastern Cooperative Oncology Group performance status 0 1 Adequate organ bone marrow function Completed prior chemotherapy last dose receive least 3 12 week prior randomization Prior therapy rapamycin rapamycin analog Ongoing toxicity associate prior anticancer therapy Another primary malignancy within past three year Concomitant medication induce inhibit CYP3A Significant , uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>